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M  RL-lpr/lpr  mice  develop  a  systemic  autoimmune 
.disease  characterized by autoantibody production in 
association  with  a  variety of inflammatory manifestations 
(1-4). Although MRL-Ipr/lpr mice develop glomerulone- 
phritis, arthritis,  and vasculitis,  genetic studies suggest that 
these  clinical  manifestations  result  from  different  patho- 
genic mechanisms  (5,  6).  In these mice, there is overpro- 
duction  of nitric  oxide  (NO) 1  ,  and  this  overproduction 
parallels  the development of clinical disease  manifestations 
(7). Compared with control mice, MRL-lpr/tpr mice have 
enhanced expression of nitric oxide synthase  type 2  (NOS2) 
in  their  spleens  and  kidneys.  In  addition,  they  have  in- 
creased levels ofnitrosylated proteins in their kidneys, indi- 
1Abbreviations used in this paper: ds, double-stranded; NO, nitric oxide; 
NOS, nitric oxide synthase; ss, single-stranded. 
Summary 
Nitric oxide (NO) is an important mediator of the inflammatory response. MRL-Ipr/lpr mice 
overexpress inducible nitric oxide synthase (NOS2) and overproduce NO in parallel with the 
development of an autoimmune syndrome with a variety of inflammatory manifestations. In 
previous studies, we showed that inhibiting NO production with the nonselective nitric oxide 
inhibitor N  -monomethyl-arginine reduced glomerulonephritis, arthritis, and  synthase (NOS)  c 
vasculitis  in MRL-lpr/lpr mice. To define further the role of NO  and NOS2  in disease  in 
MRL-Ipr/lpr mice, mice with targeted disruption of  NOS2 were produced by homologous re- 
combination and bred to MRL-lpr/lpr mice to the N4  generation. MRL-lpr/Ipr littermates 
homozygous for disrupted NOS2  (-/-),  heterozygous for disrupted NOS2  (+/-),  or wild- 
type (+/+) were derived for this study. Measures of NO production were markedly decreased 
in the MRL-Ipr/lpr (-/-)  mice compared with MRL-Ipr/Ipr (+/+)  mice, with intermediate 
production by the MRL-lpr/lpr (+/-)  mice. There was no detectable NOS2 protein by im- 
munoblot analysis of the spleen, liver, kidney, and peritoneal macrophages of the (-/-)  ani- 
mals,  whereas that of (+/+)  was high and (+/-)  intermediate. The (-/-)  mice developed 
glomerular and synovial pathology similar to that of the  (+/-)  and (+/+)  mice. However, 
(-/-)  mice and (+/-)  mice had significantly less vasculitis  of medium-sized renal vessels than 
(+/+) mice. IgG rheumatoid factor levels were significantly lower in the (-/-)  mice as com- 
pared with (+/+) mice, but levels ofanti-DNA antibodies were comparable in all groups. Our 
findings show that NO derived from NOS2 has a variable impact on disease manifestations in 
MRL-lpr/lpr mice, suggesting heterogeneity in disease mechanisms. 
cating  enhanced  NO  production  within  diseased  organs 
(8). The importance of NO to disease manifestations is fur- 
ther supported by observations that treatment of these mice 
with NQmonomethyl-t-arginine inhibits NO production 
and prevents gtomerulonephritis, arthritis, and vasculitis (7, 9). 
NO plays a key role in a number of physiologic processes 
(10,  11). As shown in recent studies,  three enzyme isoforms 
produce NO: a neuronal NOS (NOS1), an endothelial NOS 
(NOS3), and NOS2. The inducible form (NOS2) is found 
in many cell types, including mononuclear phagocytes, hepa- 
tocytes, and chondrocytes. Enhanced NOS2 expression with 
increased NO production plays an important role in host 
resistance to microbes and neoplasia (12, 13), and in various 
fomas ofinflanamation including that seen in MRL-lpr/lpr and 
SJL mice (7, 14-16). Also, patients  with rheumatoid arthritis 
overexpress NOS2 and overproduce NO (17-19). 
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rived using recombinatorial techniques (20-22). To define 
the role of NOS2 in the pathogenesis of disease in MtkL- 
Ipr/Ipr mice, mice with genetically disrupted NOS2 genes 
(NOS2 knockout mice) were bred onto the MRL-Ipr/lpr 
background for four generations. Litterrnates were derived 
that were homozygous for disrupted NOS2 [(-/-)mice], 
heterozygous for disrupted NOS2  [(+/-)  mice], or wild- 
type NOS2  [(+/+)  mice]. As shown by pathological and 
serological analyses, the absence of NOS2 had varying ef- 
fects on disease manifestations, with (-/-)  mice displaying 
equivalent degrees  of nephritis and  arthritis  as  compared 
with (+/+)  mice, while showing markedly reduced vascu- 
litis. These results suggest heterogeneity in mechanisms of 
inflammation  in MR.L-lpr/lpr mice. Furthermore, we dem- 
onstrate differences in response to inhibiting NO  produc- 
tion by a  nonspecific NOS  inhibitor in contrast with ge- 
netic disruption of the gene for NOS2. 
Methods  and  Materials 
Mice.  The  derivation  of  mice  with  genetically  disrupted 
NOS2  has  been previously described  (20). MILL-Ipr/Ipr mice 
were obtained from the Jackson Laboratories  (Bar Harbor, ME) 
and bred to  the NOS2 modified mice. Derived F1  mice were 
bred to MILL-lpr/Ipr mice to the N3 generation, and then Fas 
homozygotes were identified by PCR analysis of DNA (23), and 
used for breeding for the N4 generation to assure Fas homozy- 
gosity.  N4 MRL-Ipr/lpr  mice heterozygotic for NOS2  [(+/-) 
mice]  were  bred to  yield the  littermates  used in these  experi- 
ments. A total of 6  (+/+)  mice, 9  (+/-)  mice, and 9  (-/-) 
mice were studied.  DNA from each individual mouse was exam- 
ined by Southern blot analysis to confirm the genotype for NOS2 
(20). The animals were maintained under pathogen-free condi- 
tions at the Merck animal facility (Rahway, NJ) before transfer to 
the Durham VA Medical Center animal facility at age 12 wk. Mice 
were negative for common murine viral pathogens by sera analy- 
ses. Similarly aged female M1LL-lpr/lpr and BALB/c mice (Jack- 
son Laboratories)  were maintained in the Durham VA Medical 
Center animal facility and studied as controls. 
Specimen Collection and Nitrate~Nitrite  Measures.  Beginning  at 
12 wk of age, the mice were fed a nitrate/nitrite-free diet (Zei- 
gler Brothers,  Gardners, PA). They were placed in murine meta- 
bolic cages for 24 h every 2 wk for collection of urine. 
Urines were assessed for nitrate/nitrite concentration as a mea- 
sure of overall NO production using the Griess reagent as previ- 
ously described (7). 24-h urinary nitrite/nitrate excretion was 
calculated  and expressed  as  Ixmol/mouse/24 h~  Content of ni- 
trite/nitrate in sera and macrophage supernatants were measured 
using the same method as urinary measures and expressed as p.M. 
Protein content in 24-h urine collections (measured  using the 
BioRad Protein Assay) was used as a measure to assess glomerular 
function.  24-h  urinary protein  excretion  was  calculated  from 
urine volumes and protein concentrations. 
At 20 wk of age, the mice were bled from the retroorbital si- 
nus after  anesthesia  with fluoromethane inhalation. Mice were 
then beheaded,  and peritoneal macrophages  were  obtained by 
peritoneal lavage. The brain, lungs, liver, kidneys, lymph nodes, 
spleen,  and  knee joints were  removed.  Spleen and  all visible 
lymph nodes were weighed to assess overall lymphoid mass. Por- 
tions of each  organ were  rapidly  frozen in liquid nitrogen and 
stored at -80°C; other portions were placed in 10% formalin for 
histological study. 
Autoantibody Levels.  Anti-DNA antibody levels were  deter- 
mined by ELISA as previously described  (7). Calf thymus DNA 
(Sigma Chemical Co., St. Louis, MO) was purified by phenol ex- 
traction. Double-stranded (ds) DNA was obtained by treating the 
DNA with S1  nuclease  (Sigma); single-stranded (ss) DNA was 
derived by boiling the DNA solution for 10 min followed by im- 
mediate immersion in ice. The concentrations of DNA were de- 
termined by OD260 reading.  Purity of the DNA was assessed by 
OD260/280 ratio with a ratio  of >1.9 obtained for the DNA used 
in this study. 
Wells  of microtiter  plates  (Dynatech,  McLean,  VA)  were 
coated with 0.1 mL of either ds or ss DNA 5 ~g/mL. Sera were 
added in serial dilutions beginning at a ~00 dilution in PBS con- 
taining Tween. Peroxidase-conjugated goat anti-mouse IgG (3  ~ 
chain specific; Sigma) was added followed by 3,3',5,5' tetrameth- 
ylbenzidene (Sigma) in 0.1  M  citrate  and 0.015%  H20  2.  OD380 
absorbance was determined on a Molecular Dynamics plate reader. 
IgG and IgM rheumatoid factors in the sera were also deter- 
mined by ELISA. In brief, rabbit IgG (Sigma Chemical Co.) was 
coated on the plates in PBS at a concentration of 1 Ixg/mL. Plates 
were blocked with PBS containing BSA.  Sera  were added in 
serial  dilutions in PBS-BSA.  Peroxidase-conjugated goat  anti- 
mouse IgG (~/ chain specific) or goat  anti-mouse IgM (p, chain 
specific) were added to determine IgG and IgM rheumatoid fac- 
tor,  respectively.  IgG  3 anti-IgG2~ rheumatoid factor  levels were 
determined by ELISA  by using microtiter plates with a mouse 
IgG2a monoclonal antibody (Pharmacia, Piscataway, NJ). After ad- 
dition of serum,  peroxidase-conjugated goat  anti-mouse IgG  3 
(Southern Biotechnology  Associates, Birmingham, A.L) was added. 
To enhance measurement of cryoglobulins with rheumatoid fac- 
tor activity,  the  IgG3 assays were  run after  heating the sera to 
37°C to resuspend all precipitates and the plates and reagents were 
kept at 37°C. 
The isotype  of the  anti-DNA antibody response  was  deter- 
mined by ELISA as described above using isotype-specific  conju- 
gates  (Southern  Biotechnology  Associates, Birmingham,  AL). 
The conjugates for each isotype were assayed by titration to de- 
termine the dilution of each conjugate that yielded an OD380 ab- 
sorbance  equivalent on a Ixg/mL basis for each  IgG isotype.  All 
conjugates  were tested  for cross reactivity,  and minimal activity 
was found. The amount of anti-DNA antibody for each isotype 
in each serum was calculated, and the percentage of the total anti- 
DNA antibody response  determined. Similar assays were used to 
determine the isotype of the IgG tkF response. 
Histology.  Tissues  obtained at  post mortem dissection  were 
immediately placed in 10% buffered formalin. After fixation and 
paraffin embedding, sections were cut and stained with hematox- 
ylin and eosin. Slides were read by a pathologist  (PR.) blinded as 
to the group of mouse origin. R.enal and knee joints were graded 
according to a scale previously described  (6). Vasculitis was noted 
when present in the renal sections and graded 0-3+. 
NOS Enzyme Activity.  NOS activity was measured in freshly 
isolated  and  cultured peritoneal  macrophages  by  assessing the 
conversion of r-arginine to L-citrulline using radiolabeled  argi- 
nine as previously described  (7,  19). In brief,  cell extracts  were 
derived by 3-5 freeze-thaw cycles in PBS containing  protease in- 
hibitors.  Lysates were  collected after  centrifugation and assayed 
for protein and NOS activity, t-arginine labeled with 14C in the 
guanido position was added to the lYsates; 30 p,L of sample were 
used in a total reaction mixture of 50 txL. Samples were analyzed 
in duplicate or  triplicate.  L-arginine to  L-citrulline was  deter- 
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X8 cation exchange resin. 
ImmunoblotAnalyses.  Immunoblots  were  performed  as  de- 
scribed before  (19,  24)  using a  mouse  monoclonal anti-mouse 
NOS2 antibody (Transduction Laboratories, Lexington, KY). Pro- 
tein extracts from spleen cells were electrophoresed through a de- 
naturing polyacrylamide gel and transferred to nitrocellulose and 
processed using the enhanced chemiluminescence reagents (ECL, 
Amersham). 
Statistical Analyses.  Statistical analysis for significance was per- 
formed using the Mann-Whitney U  test (two-tailed) unless oth- 
erwise noted. 
Results 
NO  production in vivo was first determined by assaying 
24-h urinary nitrite/nitrate production.  Nitrate and nitrite 
are direct catabolites of NO  (25).  When  animals are on a 
nitrite/nitrate-free diet, serum and urine nitrite/nitrate lev- 
els reflect total body NO  production (26-28).  The  (+/+) 
mice  excreted large amounts  of nitrite/nitrate  (Fig.  1 A), 
confirming our  earlier observations  (7).  The  (+/-)  mice 
excreted intermediate levels, whereas (-/-)  mice excreted 
very low  levels of nitrite/nitrate  (comparable to  those  of 
normal BALB/c  mice).  Nitrite/nitrate levels in  sera from 
20-wk-old animals were  comparable  to  the  urinary mea- 
sures, with very low levels in the (-/-)  mice, high levels 
in the  (+/+)  mice,  and intermediate levels in the  (+/-) 
mice (Fig. 1 A). Levels of urinary and serum nitrite/nitrate 
in  (+/+)  or  (+/-)  mice  were  significantly higher  than 
those in the (-/-)  mice (P <0.003). 
To  assess  NO  production  in  vitro  by  cells,  peritoneal 
macrophages were cultured without additives and with IFN-~/ 
(50 U/mL)  and LPS (10 ng/mL)  (Fig. 1 B). Nitrite/nitrate 
levels were significantly lower in the tissue culture superna- 
tant  media  of macrophages  from  (-/-)  mice  than  (+/+) 
mice  or  (+/-)  mice,  both  without  and  with  treatment 
with LPS and IFN-'y. Similarly, NOS2 enzyme activity, as 
measured  by  the  conversion  of r-arginine  to  r-citrulline, 
was  significantly less  in  the  cells from  (-/-)  mice  than 
those from (+/-)  or (+/+)  mice (Fig. 1 B). NOS activi- 
ties were reduced by more than 90% by inclusion of 2 mM 
NG-monomethyl-r-arginine in the reaction mixtures  (data 
not  shown).  Differences  in  peritoneal  macrophage  NOS 
activity between  (-/-)  and  the  other  two  groups  were 
significant at  P  <0.0003.  These  studies  confirm a  lack of 
significant NOS activity in (-/-)  mice. 
Immunoblots were  performed on  protein extracts from 
spleens,  kidneys,  livers,  and  peritoneal macrophages  from 
the mice using an anti-NOS2 antibody. As shown in Fig. 
2, A  and B, there was no detectable NOS2  (molecular size 
~130-132  kD)  in  protein  extracts  from  spleen,  kidney, 
liver,  and  macrophages  of  (-/-)  mice;  extracts  from 
(+/+)  and  (+/-)  mice  contained  NOS2  protein,  with 
those of the (+/-)  mice having ¢'-'25-50% that of the (+/+) 
mice. As we have shown before (7), extracts from cells and 
tissues of normal mice (e.g., BALB/c mice) had no detect- 
able NOS2 antigen. 
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Figure 1.  (A) Nitrate and nitrite in urine, serum, and peritoneal mac- 
rophage supernatant medium from NOS2-modified MRL-lpr/lpr  mice. 
20-wk-old mice  were  examined. Serum  and  urine  were  collected as 
noted in Materials and Methods. Resident peritoneal macrophages were 
cultured for 3 d with 10 ng/mL and 50 U/mL of routine IFN-~/present 
in the culture for 3 d. Urine values are presented as p.mol/day, while Se- 
rum and Mac supt. values are presented as p,M. The bars display  the 
means and one standard deviation from mice of the designated groups. (B) 
NOS  activity in  extracts from  cultured  peritoneal  macrophages from 
NOS2-modified MRL-lpr/lpr mice. 20-wk-old mice were examined. The 
bars display  the means and one standard deviation from mice of the desig- 
nated groups. Peritoneal macrophages  were cultured 3 d with no additives 
(no addition), or with 10 ng/mL of LPS and 50 U/mL of murine IFN-~ 
(LPS/IFN) present in the culture for 3 d. 
Based  on  the  effect  of in  vivo  administration  of N g- 
monomethyl-r-arginine  on  renal  disease  and  arthritis  in 
MRL-Ipr/Ipr  mice  (7),  we  predicted  that  (-/-)  mice 
would develop less renal disease and arthritis than mice of 
the  other  two  groups.  However,  pathologic  examination 
indicated that  glomerulonephritis in  the  (-/-)  mice was 
similar in severity to that of the other two groups. Prohfer- 
367  Gilkeson et al. Figure 2.  (A and B) Anti-NOS2 immunoblot of tissue and cell extracts from NOS2-modi- 
fled MRL-lpr/lpr  mice. 20-wk-old mice were examined. Extracts from kidney, spleen, and 
liver of(+/+), (+/-) , (-/-) and BALB/c (B) mice are displayed in A, and that for perito- 
neal macrophages in B. For negative and positive controls, we used extracts from the mouse 
macrophage cell line  J774 without (0) or with LPS and IFN-31  (L/). The predominant band ap- 
peared at a region corresponding  to about 130 kD. 
ative  glomerulonephritis  was present  in all  mice regardless 
of NOS2  genotype, with  overall glomerular scores similar 
between the groups (Figs.  3 A  and 4 A). Crescentic glom- 
erulonephritis and interstitial disease were present in a small 
number of mice in each group. 24-h urinary protein excre- 
tion at 20 wk of age was less in the (-/-)  mice than in the 
other  two  groups  (4.5  -+  2.8  [mean  -+  SD]  mg/day for 
[+/+],  2.6  +  3.0 for [+/-],  and  1.9  -+  0.5  for [-/-]), 
but  these  were  not  statistically  different.  Synovitis  was 
present  in  the  majority  of the  mice  with  overall  synovial 
scores  similar  in  the  three  groups.  Synovial hypertrophy, 
synovial inflammation,  and erosive disease were present to 
a  similar  degree  in  the  MRL-Ipr/Ipr mice  regardless  of 
NOS2 genotype (Figs. 3 A  and 4/3). 
In  contrast  with  the  findings  with  glomerulonephritis 
and arthritis,  there was a significant difference in the pres- 
ence and severity of vasculitis observed in renal vessels de- 
pending  on  NOS2  genotype  (Figs.  3  B,  4,  C  and  4  D). 
Four  of six  (+/+)  mice  had  prominent  vasculitis  in  the 
kidney,  whereas  one of nine  of the  (+/-)  mice and zero 
of nine  of (-/-)  mice had vasculitis  (Fig.  4  C  and 4  D). 
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The incidence  ofvasculitis in the  (+/+)  mice was similar 
to  that  in  20-wk-old  female  MRL-lpr/Ipr control  mice 
(80%).  The  difference  in  the  occurrence  of vasculitis  be- 
tween the (+/+)  mice and the (--/-)  mice was significant 
at P  <0.015. 
Histological examination of the brain, liver, lymph nodes, 
spleen,  and lung revealed similar mild lymphocytic infiltra- 
tion in all three groups. Although the combined spleen and 
lymph  node  weights  were  less  in  the  (-/-)  mice  com- 
pared with  the  (+/+)  mice,  the differences were not sig- 
nificant  (Table  1).  Hematocrits were slightly higher in the 
(-/-)  mice than in the other two groups, but these differ- 
ences were not significant (Table 1). 
Autoimmune  disease  in MR.L-Ipr/Ipr  mice is  associated 
with production of a variety of autoantibodies  th~ are ob- 
served in both human rheumatoid arthritis and systemic lu- 
pus erythematosus (1-3). Therefore, we determined whether 
MRL-Ipr/lpr mice  of various  NOS2  genotypes  displayed 
qualitative  or quantitative  differences  in  autoantibody  pro- 
duction.  As shown in  Fig.  5  A,  serum levels  of antibodies 
to  ss  or  dsDNA  did  not  differ  among  the  various  mice, 1 
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Figure 3.  (./t and B) Pathologic features of NOS2-modified MRL-lpr/lpr  mice. 20-wk-old mice were examined. The bars show the mean and one stan- 
dard deviation for the designated groups for renal and joint scores (A), and vessel scores (/3). 
although there was a shift in the isotype ofanti-DNA an- 
tibodies produced. The IgG1/IgG3 ratio of anti-DNA an- 
tibodies  was  higher  in  the  (-/-)  than  in  (+/+)  mice 
(1.31  versus  0.39).  In  contrast  with  anti-DNA  antibody 
levels,  RF levels differed among the MRL-Ipr/Ipr mice  of 
various NOS2 genotypes. The (-/-)  mice produced sig- 
nificandy less IgG tLF and IgM RF than did (+/+)  mice 
(Fig.  5  B).  IgG3 rheumatoid  factor activity (known  to be 
associated with small vessel, but not medium vessel vasculi- 
tis in MtLL-lpr/lpr mice; reference 29),  was similar in the 
three  groups  of mice  [(+/+),  0.733  ±  0.215;  (+/-), 
0.633  -  0.362;  and (-/-),  0.781  ±  0.278].  Total serum 
lgG and IgM were similar in the three groups as were se- 
rum levels  of anti-Sm and  anti-La  antibodies  (results  not 
shown). 
Discussion 
Our results indicate that absence of a functional gene for 
NOS2 has variable effects on disease  manifestations in au- 
toimmune MtLL-lpr/lpr mice. Thus, although (-/-)  mice 
developed glomerular and synovial pathology of similar se- 
verity to that noted in (+/-)  or (+/+)  mice, they had re- 
duced vasculitis.  There was  a trend  toward reduced  renal 
disease  (manifested by proteinuria)  with  decreasing  num- 
bers  of NOS2  genes.  However,  the  differences were not 
statistically significantly different.  This finding could indi- 
cate that lack of NOS2 lessens some manifestations of renal 
disease in these mice, and that if the mice had been exam- 
ined  at  a  later  timepoint,  significant  differences  in  pro- 
teinuria  and  renal  histology might have been noted.  The 
(-/-)  mice  had  significantly lower  serum levels  of IgG 
P,.F levels than did  (+/+)  or (+/-)  littermates, but total 
Ig levels and levels of other autoantibodies were unaltered. 
The varying effects of a lack of functional NOS2  on au- 
toimmune disease likely reflect differences in the pathogen- 
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esis of these abnormalities. Indeed, studies in MRL-lpr/Ipr 
mice indicate that clinical manifestations of autoimmunity 
can be genetically separated by backcross breeding to other 
strains.  Mapping of susceptibility loci in MRL-lpr/Ipr mice 
indicate that the expression of glomerulonephritis, arthritis, 
and vasculitis are dependent on separate genetic loci (1,  5, 
6).  Of note,  susceptibility to vascuhtis is distinct from the 
susceptibility to glomerulonephritis  (5).  This result implies 
that in MRL-lpr/lpr mice different pathogenic mechanisms 
for these  two manifestations exist,  and our results suggest 
that  vasculitis  is  dependent  on  NOS  and  NO,  whereas 
glomerulonephritis and synovitis are not. 
Results of the current study suggest that the development 
of vascuhtis in MRL-Ipr/lpr  mice requires the presence of a 
functional  NOS2  gene  and  NOS2-generated  NO.  Sup- 
porting  this  notion,  analysis  of samples  from  our  earlier 
study (7) showed that NG-monomethyl-t-arginine treatment 
also  decreased the  incidence  of vasculitis in MRL-lpr/lpr 
mice (4 of 10 untreated controls developed vasculitis, com- 
pared  with  1  of 9  mice  treated  with  NG-monomethyl  - 
r-arginine) (Gilkeson and Weinberg, unpublished data)]. Thus, 
it appears that while NOS2 overexpression and NO over- 
production contribute to glomerulonephritis,  arthritis,  and 
vasculitis in MRL-lpr/lpr  mice (7), vasculitis requires an in- 
tact NOS2 response. The role of NOS2 and NO in vascu- 
lifts has been demonstrated in other studies.  Pulmonary vascu- 
lifts in  rats,  induced  by infusion  of immune complexes, is 
characterized by enhanced  local production  of NO.  Fur- 
thermore, inhibiting NO production with L-arginine ana- 
logues prevents the vasculitis despite deposition of immune 
complexes in the pulmonary vessels (30,  31). In this regard, 
(+/-)  mice as well as (-/-)  mice have reduced vasculitis. 
These findings, while observed with only a limited number 
of mice,  raise the possibility that even partial  inhibition of 
NOS2  activity pharmacologically would  be beneficial.  We 
do not fully understand  the cause of this heterozygote ef- Figure 4.  (A, B, C, and D) Histology of tissues from NOS2-modified MRL-lpr/lpr  mice. 20-wk-old mice were examined. A shows a representative 
section from kidney of a (-/-)  MRL-lpr/lpr  mouse, demonstrating glomerulonephritis with inflammation, sclerosis,  and crescent formation. Compara- 
ble lesions were observed in (+/+ ) mice and in (+/-) mice. B shows a representative section of a knee joint from a (-/-) MRL-lpr/lpr  mouse. There 
is synovial proliferation and inflammation. Comparable lesions were observed in (+/+) mice and in (+/-) mice. C and D show kidney sections con- 
taining medium-sized arterioles from MRL-lpr/lpr (+/÷) (C) and (-/-)  (D) mice. That from the (+/+) a mouse in C demonstrates vasculitis,  whereas 
that from a (-/-)  mouse in D is essentially  normal with no evidence ofvasculitis. (Hematoxylin and eosin stain; original magnifications  200×). 
fect,  but  it  could  indicate  a  threshold  effect  for  NO  and 
vasculitis. For vasculitis, there may be a certain threshold of 
NO  production  (a level greater than  50%  of that noted in 
[+/+]  mice) that is required for disease manifestation. Al- 
ternatively,  there  may  be  more  complex  mechanisms  at 
Table 1.  Lymphoid  Mass and Hematocrits in NOS2-modified 
MRL-lpr/lrp Mice* 
MRL-lpr/lpr  Spleen  Lymph node 
NOS2 genotype  weight*  weight  Hematocrit~ 
(+/+)  0.80 +  0.34~  3.70 +  0.51  31.7  q- 0.8 
(+/--)  0.58 ±  0.26  2.86  +  1.15  31.4  +  2.6 
(--/--)  0.68 --+ 0.28  3.12 ±  1.50  33.0  -+ 0.0 
*All weights are expressed in grams. 
*Volume/volume (mean +  SD). 
~Mean +  SD. 
work to  explain this.  These would include interactions of 
NO  with other factors involved in inflammation (e.g., cy- 
clooxygenase 2  and arachidonic acid metabofites). 
In  our  study,  (-/-)  mice  (despite equivalent levels of 
anti-DNA  antibodies  and  total  IgG)  showed  significantly 
reduced levels oflgG RF compared with (+/-)  and (+/+) 
mice when tested with heterologous IgG. The reduction of 
these RF may be related to a direct effect of NO  on B  cells 
since, as shown by Genaro and others, NO  protects B  cells 
from apoptosis through a Bcl-2-dependent mechanism  (32). 
In  the  absence  of NOS2-derived  NO,  RF-producing B 
cells may undergo apoptosis (presumably by a Fas-indepen- 
dent mechanism; reference 33). In this regard, the effects of 
NOS2 gene disruption on this type of RF production may 
be  more  pronounced  than  the  effects  on  other  autoanti- 
bodies because of differences in the activation requirements 
in this response.  Thus,  as shown  in other studies, IgG RF 
occurs  more  sporadically  in  MRL-lpr/lpr  mice  than  do 
anti-DNA antibodies;  furthermore,  RF  levels are  not  di- 
rectly related to  the extent of hyperglobulinemia, suggest- 
ing antigen-specific regulatory interactions (34).  These in- 
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Figure 5.  (A and B) Anti-DNA and anti-lg rheumatoid factor antibody activity in sera from NOS2-modified MR.L-lpr/Ipr  mice. 20-wk-old mice 
were examined. A shows results from experiments testing sera for anti-ss-DNA antibody and anti-dsDNA antibody activity, and B shows results from ex- 
periments testing sera for IgG and IgM anti-lg (rheumatoid factor) activity. The bars display the means and one standard deviation. 
teractions may confer an increased sensitivity to the effects 
of NO. 
Although  the  basis  for  the  reduced  RF  production  in 
(-/-)  mice is not clear,  this  reduction may be linked  to 
the decrease in the observed frequency and intensity ofvas- 
culitis.  IgG RF production occurs prominently in humans 
with vasculitis,  as well as in MRL-lpr/Ipr mice.  These au- 
toantibodies  most likely promote vasculitis because  of the 
formation of immune complexes that deposit in the vessel 
and  stimulate  local  inflammation.  In  MRL-lpr/Ipr  mice, 
IgG  3 RF have been implicated in small vessel disease  (35). 
However,  RF of this isotype were found in  (-/-)  mice, 
despite  the  absence  of vasculitis  and  overall  reduction  of 
RF  autoantibodies.  Together  with  studies  on  anti-DNA 
antibody levels, these finding suggest that the effects of NO 
on pathogenic autoantibody responses are complex and in- 
fluence the overall magnitude of these responses as well as 
the expression of particular antibody isotypes. 
The mechanism(s)  for the contrasting effects on renal and 
synovial  diseases  of a  genetically  disrupted  NOS2  as  op- 
posed to pharmacological inhibition  of NOS activity with 
NG-monomethyl-r-arginine is not clear.  It is unlikely that 
there were compensatory increases  in NOS1  or NOS3 in 
the (-/-)  mice, because we noted very low total body NO 
production  in  the  (-/-)  mice.  NG-monomethyl-r-argi- 
nine is an isoform-nonspecific NOS inhibitor, blocking all 
three isoforms of the NOS enzymes (36). Inhibiting all NOS 
isoforms  (and  hence  potentially  all  NO  production)  with 
NG-monomethyl-r-arginine may be more effective in dis- 
ease prevention than genetically disrupting only NOS2. Al- 
ternative  inflammatory pathways  may not  be  active  when 
NO  production  is  acutely  blocked  by  NQmonomethyl- 
r-arginine;  however,  these pathways might become active 
over time when NOS2 is genetically disrupted and absent 
the entire life of the animal. 
Studies using NG-monomethyl-r-arginine in MRL-Ipr/Ipr 
mice indicate  that NO  is important in the pathogenesis of 
glomerulonephritis,  arthritis,  and vasculitis  (7,  9).  However, 
the  work reported  here  studying inflammation  in  MRL- 
lpr/lpr mice with genetically disrupted NOS2 highlights the 
heterogeneity and complexity of the role NOS2 and NO. 
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